Ham­mered by a se­ries of set­backs, NewLink ax­es staff (again) and cir­cles its wag­ons around trou­bled IDO pro­gram

Three months af­ter NewLink Ge­net­ics scrapped a com­bi­na­tion pro­gram for its IDO path­way drug in­dox­i­mod in the gen­er­al rout that fol­lowed the fail­ure of In­cyte’s big IDO project for epaca­do­stat, the biotech is nev­er­the­less cir­cling its wag­ons around a last stand ef­fort to prove their ther­a­py can work and make it to the mar­ket. In the process, the Iowa-based com­pa­ny has slashed close to a third of its staff and re­or­ga­nized the C suite in the process.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER